Dysphonia associated with the use of inhaled corticosteroids

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 23, Issue 3, 2015, Pages 255-259

  Chmielewska, Monika ^a   Akst, Lee M ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

dysphonia; inhaled corticosteroids; reactive airway disease

Indexed keywords

BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; PROPELLANT; TRIAMCINOLONE ACETONIDE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CONSERVATIVE TREATMENT; DRUG DELIVERY SYSTEM; DYSPHONIA; ELECTROMYOGRAPHY; ENDOSCOPY; HUMAN; INHALER; LARYNX DISORDER; METERED DOSE INHALER; OROPHARYNX CANDIDIASIS; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; CHEMICALLY INDUCED; INHALATIONAL DRUG ADMINISTRATION; NEBULIZER;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; DYSPHONIA; HUMANS; NEBULIZERS AND VAPORIZERS;

EID: 84960102241     PISSN: 10689508     EISSN: 15316998     Source Type: Journal    
DOI: 10.1097/MOO.0000000000000153     Document Type: Review

References (52)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention; 2004. www.ginasthma.org. [Accessed 15 December 2014]
2. National Institutes of Health. National Asthma Education and Prevention Programme. Expert Panel Report:Guidelinesforthe Diagnosisand Management of Asthma. Bethesda, MD: National Institutes of Health; 1997; 97-4051.
3. National Institutes of Health, National Heart, Lung and Blood Institute. National Asthma Education and Prevention Programme Expert Panel Report: guidelines for the diagnosis and management of asthma update on selected topics 2002. J Allergy Clin Immunol 2002; 110:S142-S219.
4. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343:332-336.
5. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticoster-oids: new developments. Am J Respir Crit Care Med 1998; 157 (3 pt 2):S1-S53.
6. Pandya D, Puttanna A, Balagopal V. Systemic effects of inhaled corticosteroids: an overview. Open Respir Med J 2014; 8:59-65.
7. Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis. Ann Allergy Asthma Immunol 2007; 98:225-238.
8. Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 2004; 44:37-47.
9. Moreira Veiga de Souza A, De Campos Duprat A, Cardoso Costa R, et al. Use of inhaled versus oral steroids for acute dysphonia. Braz J Otorhinolaryngol 2013; 79:196-202.
10. De Corbiere S, Freche C. Corticotherapy in ENT. Subglottic laryngitis in children, acute sinusitis, naso-sinusal polyposis, sero-mucous otitis. Ann Med Interne (Paris) 1998; 149:508-511.
11. Spiegel JR, Hawkshaw M, Sataloff RT. Dysphonia related to medical therapy. Otolaryngol Clin North Am 2000; 33:771-784.
12. Sataloff RT, Shaw A, Markiewicz A. Acute laryngitis in a professional singer. Ear Nose Throat J 2001; 80:436.
13. Watts CR, Clark R, Early S. Acoustic measures of phonatory improvement secondary to treatment by oral corticosteroids in professional singer: a case report. J Voice 2001; 15:115-121.
14. Klassen TP. Recents advances in the treatment of bronchiolitis and laryngitis. Pediatr Clin North Am 1997; 44:249-261.
15. Ingle JW, Helou LB, Li NY, et al. Role of steroids in acute phonotrauma: a basic science investigation. Laryngoscope 2014; 124:921-927.
16. DelGaudio JM. Steroid inhaler laryngitis: dysphonia caused by inhaled fluti-casone therapy. Arch Otolaryngol Head Neck Surg 2002; 128:677-681.
17. Watts CR, Early S. Corticosteroids: effects on voice. Curr Opin Otolaryngol Head Neck Surg 2002; 10:168-172.
18. Hillel AT, Lin LM, Samlan R, et al. Inhaled triamcinolone with proton pump inhibitor for treatment of vocal process granulomas: a series of 67 granulo-mas. Ann Otol Rhinol Laryngol 2010; 119:325-330.
19. Dogan M, Eryuksel E, Kocak I, et al. Subjective and objective evaluation of voice quality in patients with asthma. J Voice 2007; 21:224-230.
20. Lee L, Chamberlain LG, Loudon RG, Stemple JC. Speech segment durations produced by healthy and asthmatic subjects. J Speech Hear Disord 1988; 53:186-193.
21. Lee L, Friesen M, Lambert I, Loudon R. Evaluation of dyspnea during physical and speech activities in patients with pulmonary diseases. Chest 1998; 113:625-632.
22. Bartfield JM, Ushkow BS, Rosen JM, et al. Single breath counting in the assessment of pulmonary function. Ann Emerg Med 1994; 24:256-259.
23. Vogt FC. The incidence of oral candidiasis with use of inhaled corticosteroids. Ann Allergy 1979; 43:205-210.
24. Galvey SV, Keane N, Power M, et al. Posterior pharyngeal candidiasis in the absence of clinically overt oral involvement: a cross-sectional study. Lung 2013; 191:663-668.
25. Toogood JH, Jennings B, Bakersville J, et al. Dosing regimen of budesonide and occurrence of oropharyngeal complications. Eur J Respir Dis 1984; 65:35-44.
26. Toogood JH. Complications of topical steroid therapy for asthma. Am Rev Repir Dis 1990; 141:S89-S96.
27. Knight L, Fletcher J. Growth of Candida albicans in saliva: stimulation by glucose associated with antibiotics, corticosteroids, and diabetes mellitus. J Infect Dis 1971; 123:371-377.
28. Ellepola AN, Samaranayake LP. Inhalational and topical steroids, and oral candidosis: a mini review. Oral Dis 2001; 7:211-216.
29. Simon MR, Houser WL, Smith KA, Long PM. Esophageal candidiasis as a complication of inhaled corticosteroids. Ann Allergy Asthma Immunol 1997; 79:333-338.
30. Fidel PL Jr. Distinct protective host defenses against oral and vaginal candidiasis. Med Mycol 2002; 40:359-375.
31. Fukushima C, Shimoda T, Kawano T, et al. Effects of amphotericin B gargles on oral colonization of Candida albicans in asthmatic patients on steroid inhalation therapy. Respiration 2001; 68:465-470.
32. Wong KK, Pace-Asciak P, Morrison MD. Laryngeal candidiasis in the outpatient setting. J Otolaryngol Head Neck Surg 2009; 38:624-627.
33. Williams MLT Jr, Kane C, Shim CS. Treatment of asthma with triamcinolone acetone delivered by aerosol. Am Rev Respir Dis 1974; 109:538-543.
34. Lavy JA, Wood G, Rubin JS, Harris M. Dysphonia associated with inhaled steroids. J Voice 2000; 14:581-588.
35. Flovent Inhalation Aerosol (fluticasone propionate inhalation powder) [product information for 44 mcg, 110 mcg, and 220 mcg dose from the actuator and 50, 125, 250 from the valve]. Research Triangle Park, NC: Glaxo Wellcome Inc, 2004. http://us.gsk.com/products/assets/us-flo-vent.pdf. [Accessed 24 October 2005].
36. Pulmicort Turbuhaler 200 mcg [prescribing information]. Wilmington, DE: Astra Zeneca, 2001. http://www.astra-zeneca-us.com/pi/pulmicortturboha ler.pdf. [Accessed 24 October 2005].
37. Azamacort (triamcinolone acetonide) inhalation aerosol [prescribing information]. Bridgewater, NJ: Aventis Pharmaceuticals Inc, 2003. http://www.theo dora.com/drugs/azmacort-inhalation-aerosol-kos.html. [Accessed 25 October 2005]
38. Alvesco (ciclesonide) inhalation solution (prescribing information for 40 mcg, 80 mcg, and 160 mcg dose). Konstanz, Germany: ALTANA Pharma, Alvesco MRP, 2004. http://www.respistory.com/aa/ast/treatments-alvesco.html?ut m-source=BrandButton&utm-medium=website&utm-content=ALV-PTBTH OME&utm-campaign=Alvesco&utm-term=ALV-PTBTHOME. [Accessed 16 December 2014]
39. Engelstatter R, Banerji D, Steinijans VW, Wurst W. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide: results from a pooled analysis [abstract]. Am J Respir Crit Care Med 2004; 169 (Suppl); A92.
40. Sahrawat R, Robb MP, Kirk R, et al. Effects of inhaled corticosteroids on voice production in healthy adults. Logoped Phoniatr Vocol 2014; 39: 108-116.
41. Tuzuner A, Demirci S, Bilgin G, et al. Voice assessment after treatment of subacute and chronic cough with inhaled steroids. J Voice 2015. [Epub ahead of print]
42. Mirza N, Kasper Schwartz S, Antin-Oserkis D. Laryngeal findings in users of combination corticosteroid and bronchodilator therapy. Laryngoscope 2004; 114:1566-1569.
43. Williams AJ, Baghat MS, Stableforth DE, et al. Dysphonia caused by inhaled steroids: recognition of a characteristic laryngeal abnormality. Thorax 1983; 38:813-821.
44. Acar GO, Adatepe NU, Kaytaz A, et al. Evaluation of laryngeal findings in users of inhaled steroids. Eur Arch Otorhinolaryngol 2010; 267:917-923.
45. Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: does it matter? J Allergy Clin Immunol 2009; 124 (Suppl 6):S88-S93.
46. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994; 7:1839-1844.
47. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 2004; 126:212-219.
48. Leach CL, Bethke TD, Boudreau RJ, et al. Two-dimensional and three dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. J Aerosol Med 2006; 19:117-126.
49. Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol 2005; 61:203-208.
50. Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 2005; 94: 465-472.
51. Toogood JH, Jennings B, Greenway RW, Chuang L. Candidiasis and dys-phonia complicating beclomethasone treatment of asthma. J Allergy Clin Immunol 1980; 102:592-594.
52. Gallivan GJ, Gallivan KH, Gallivan HK. Inhaled corticosteroids: hazardous effects on voice-an update. J Voice 2007; 21:101-111.